685 related articles for article (PubMed ID: 20026854)
1. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
Love WE; Bernhard JD; Bordeaux JS
Arch Dermatol; 2009 Dec; 145(12):1431-8. PubMed ID: 20026854
[TBL] [Abstract][Full Text] [Related]
2. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
Tillman DK; Carroll MT
Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
[TBL] [Abstract][Full Text] [Related]
3. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical delta-aminolevulinic acid photodynamic therapy.
Fink-Puches R; Soyer HP; Hofer A; Kerl H; Wolf P
Arch Dermatol; 1998 Jul; 134(7):821-6. PubMed ID: 9681345
[TBL] [Abstract][Full Text] [Related]
5. Imiquimod: in superficial basal cell carcinoma.
Oldfield V; Keating GM; Perry CM
Am J Clin Dermatol; 2005; 6(3):195-200; discussion 201-2. PubMed ID: 15943496
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma.
Bostanci S; Kocyigit P; Vural S; Heper AO; Botsali A
Dermatol Surg; 2018 Jan; 44(1):36-41. PubMed ID: 29016542
[TBL] [Abstract][Full Text] [Related]
7. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
Vidal D; Matías-Guiu X; Alomar A
Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens.
Shumack S; Robinson J; Kossard S; Golitz L; Greenway H; Schroeter A; Andres K; Amies M; Owens M
Arch Dermatol; 2002 Sep; 138(9):1165-71. PubMed ID: 12224977
[TBL] [Abstract][Full Text] [Related]
9. Treatment of cutaneous tumors with topical 5% imiquimod cream.
Alessi SS; Sanches JA; Oliveira WR; Messina MC; Pimentel ER; Festa Neto C
Clinics (Sao Paulo); 2009; 64(10):961-6. PubMed ID: 19841702
[TBL] [Abstract][Full Text] [Related]
10. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.
Huber A; Huber JD; Skinner RB; Kuwahara RT; Haque R; Amonette RA
Dermatol Surg; 2004 Mar; 30(3):429-30. PubMed ID: 15008876
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature.
Drehs MM; Cook-Bolden F; Tanzi EL; Weinberg JM
Dermatol Surg; 2002 May; 28(5):427-9. PubMed ID: 12030878
[TBL] [Abstract][Full Text] [Related]
12. Imiquimod induces sustained remission of actinic damage: a case report spanning one decade of observation.
Knackstedt TJ; Quitadamo M
Cutis; 2015 Feb; 95(2):E20-3. PubMed ID: 25750973
[TBL] [Abstract][Full Text] [Related]
13. Topical treatment of basal cell carcinoma with the immune response modifier imiquimod.
Papakostas D; Stockfleth E
Future Oncol; 2015 Nov; 11(22):2985-90. PubMed ID: 26450707
[TBL] [Abstract][Full Text] [Related]
14. Conventional and combination topical photodynamic therapy for basal cell carcinoma: systematic review and meta-analysis.
Collier NJ; Haylett AK; Wong TH; Morton CA; Ibbotson SH; McKenna KE; Mallipeddi R; Moseley H; Seukeran D; Ward KA; Mohd Mustapa MF; Exton LS; Green AC; Rhodes LE
Br J Dermatol; 2018 Dec; 179(6):1277-1296. PubMed ID: 29889302
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma.
Arits AH; Spoorenberg E; Mosterd K; Nelemans P; Kelleners-Smeets NW; Essers BA
Br J Dermatol; 2014 Dec; 171(6):1501-7. PubMed ID: 24749843
[TBL] [Abstract][Full Text] [Related]
16. A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer.
Marmur ES; Schmults CD; Goldberg DJ
Dermatol Surg; 2004 Feb; 30(2 Pt 2):264-71. PubMed ID: 14871220
[TBL] [Abstract][Full Text] [Related]
17. Treatment of facial superficial basal cell carcinomas with imiquimod 5% cream.
Mirza B; De'Ambrosis B
Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():16-8. PubMed ID: 14616806
[TBL] [Abstract][Full Text] [Related]
18. Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week period: a case series.
Ruiz-Villaverde R; Sánchez-Cano D; Burkhardt-Pérez P
J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):828-31. PubMed ID: 19646136
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome after treatment with 5% topical imiquimod cream in patients with basal cell carcinoma of the eyelids.
Prokosch V; Thanos S; Spaniol K; Stupp T
Graefes Arch Clin Exp Ophthalmol; 2011 Jan; 249(1):121-5. PubMed ID: 20886224
[TBL] [Abstract][Full Text] [Related]
20. Tumor thickness and adnexal extension of superficial basal cell carcinoma (sBCC) as determinants of treatment failure for methylaminolevulinate (MAL)-photodynamic therapy (PDT), imiquimod, and 5-fluorouracil (FU).
Roozeboom MH; van Kleef L; Arits AH; Mosterd K; Winnepenninckx VJ; van Marion AM; Nelemans PJ; Kelleners-Smeets NW
J Am Acad Dermatol; 2015 Jul; 73(1):93-8. PubMed ID: 25935596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]